University Hospital, Antwerp
uza.beTotal trials
237
Active
69
Phase 3
9
Total enrollment
45,583
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 22 of 22 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Somatostatin analog | — | — | — | — | — | 1 | |
| Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids. | — | — | — | — | — | 1 | |
| Glucose 5% for fluid creep | — | — | — | — | — | 1 | |
| NaCl 0.9% (normal saline) for fluid creep | — | — | — | — | — | 1 | |
| PlasmaLyte as maintenance fluid | — | — | — | — | — | 1 | |
| NaCl 0.3% in glucose 3.3% as maintenance fluid | — | — | — | — | — | 1 | |
| Acetazolamide | — | — | — | — | 3 | ||
| Methylprednisolone 125 MG | — | — | — | — | — | 1 | |
| acetylsalicylic acid | — | — | — | — | — | 1 | |
| tolerogenic dendritic cells | — | — | — | — | 3 | ||
| Dendritic cell vaccine plus temozolomide chemotherapy | — | — | — | — | — | 1 | |
| Neoadjuvant chemo-immunotherapy | — | — | — | — | — | 1 | |
| IL15-transpresenting WT1-targeted Dendritic Cell Vaccine | — | — | — | — | — | 1 | |
| Metformin Hydrochloride 850 mg Oral | — | — | — | — | — | 1 | |
| Dendritic cell vaccination | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| Platinum/pemetrexed based chemotherapy | — | — | — | — | — | 1 | |
| Dendritic cell vaccination + temozolomide-based chemoradiation | — | — | — | — | — | 1 | |
| Dendritic cell vaccination +- conventional next-line treatment | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| 6-mercaptopurine | — | — | — | — | — | 1 | |
| Probiotic throat spray | — | — | — | — | — | 1 |
Next readouts
- 2023-04-22
- 2024-11-01
- 2024-12
- 2024-12
- 2025-09-28
- 2026-10
- 2026-10-01
- 2026-12-31
- 2027-02-28
- 2027-06-01
Top conditions
- Obstructive Sleep Apnea16
- Tinnitus8
- Surgery5
- Multiple Sclerosis5
- Type 1 Diabetes4
- Chronic Obstructive Pulmonary Disease4
- Sleep Apnea4
- Hyperacusis3
Frequently asked questions about University Hospital, Antwerp
- How many clinical trials does University Hospital, Antwerp have on ClinicalTrials.gov?
- University Hospital, Antwerp is listed as the lead sponsor on 237 clinical trials in ClinicalTrials.gov, 69 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Antwerp's trials are in Phase 3?
- 9 of University Hospital, Antwerp's trials are in Phase 3, spread across 22 active drug programs.
- What therapeutic areas does University Hospital, Antwerp focus on?
- University Hospital, Antwerp's most-studied conditions on ClinicalTrials.gov are Obstructive Sleep Apnea, Tinnitus, Surgery, Multiple Sclerosis, Type 1 Diabetes.
- When are University Hospital, Antwerp's next clinical trial readouts?
- University Hospital, Antwerp has 10 upcoming primary-completion readouts tracked here; the soonest is “Acetazolamide Add-On Therapy to OSA Surgery”, expected around 2023-04-22.